• Corpus ID: 79344833

The Effect of Novel Anti-inflammatory Drugs on the Cyclooxygenase Enzymes and Recovery of Mucosal Barrier Function

  title={The Effect of Novel Anti-inflammatory Drugs on the Cyclooxygenase Enzymes and Recovery of Mucosal Barrier Function},
  author={John F Marshall},
MARSHALL, JOHN FRASER. The Effect of Novel Anti-inflammatory Drugs on the Cyclooxygenase Enzymes and Recovery of Mucosal Barrier Function. (Under the direction of Anthony T Blikslager). The non-steroidal anti-inflammatory drugs (NSAIDs) are a large group of drugs that are commonly used for the treatment of pain and inflammation in the veterinary species. The NSAIDs inhibit the action of the cyclooxygenase (COX) enzymes, COX-1 and COX-2, to reduce the production of prostaglandins. However, their… 
Biochemical and epidemiological investigations of non-steroidal anti-inflammatory drug usage and related side effects in equids
Findings from experimental settings are confirmed that NSAIDs firocoxib is COX-2 selective and that flunixin meglumine and phenylbutazone are non-selective COX inhibitors and therefore their administration carries a greater risk of toxicity.


Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility.
  • B. Cronstein
  • Medicine, Biology
    Cleveland Clinic journal of medicine
  • 2002
This review summarizes some of the key aspects of COX biochemistry, structure, and function and the evolution of understanding the mechanism of action ofCOX-2-selective inhibitors to provide a framework upon which clinicians can better appreciate current and future therapeutic applications of coxibs.
Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs
Analysis of the ratio of inhibition ofCOX-1 to COX-2 by non-steroidal anti-inflammatory drugs, suggests inhibitors can be classified based on their COX selectivity, and human pharmacology studies concentrating on the inhibition of prostanoid synthesis in target tissues are of paramount importance in determining the clinical relevance of COx-2 selectivity.
Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib.
The objectives of this study were to quantify the inhibitory actions of robenacoxib on cyclooxygenase (COX) isoenzymes in feline whole blood assays, and to establish blood concentration-time profiles ofRobenacxib after intravenous and subcutaneous dosing in the cat and to predict the time courses of inhibition of COX isoforms by robenACoxib.
Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum.
Treatment of horses with ischaemic jejunal disease with flunixin may result in a prolonged permeability defect in recovering mucosa, which may have implications for the use of nonsteroidal anti-inflammatory drugs in colic patients.
A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes.
  • J. Frölich
  • Medicine, Biology
    Trends in pharmacological sciences
  • 1997
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
Results of preclinical studies in rats studies suggest that robenacoxib has an attractive pharmacological profile for potential use in the intended target species, cats and dogs.
Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest.
This review summarises selected aspects of the pharmacokinetics (PK) and pharmacodynamics (PD) of nonsteroidal anti-inflammatory drugs (NSAIDs) which are important to an understanding of PK- PD integration and PK-PD modelling (the subject of the next review in this issue).
Effects of ischemia and the cyclooxygenase inhibitor flunixin on in vitro passage of lipopolysaccharide across equine jejunum.
Evaluated the clinical importance of flunixin-associated delayed mucosal recovery requires further in vivo investigation, and ischemia increased LPS passage across equine jejunal mucosa.
In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats.
The novel DFU was the most selective COX-2 inhibitor in equine, canine, and feline blood, compared with phenylbutazone, flunixin meglumine, and carprofen and may result in a lower incidence of adverse effects compared with NSAID.